4565 Stock Overview
Develops and sells biopharmaceutical products in Japan, Switzerland, the United States, Bermuda, and the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 4565 from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Nxera Pharma Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥1,048.00 |
| 52 Week High | JP¥1,826.00 |
| 52 Week Low | JP¥1,008.00 |
| Beta | 0.66 |
| 1 Month Change | -3.05% |
| 3 Month Change | -16.23% |
| 1 Year Change | -30.60% |
| 3 Year Change | -39.21% |
| 5 Year Change | -50.45% |
| Change since IPO | -48.50% |
Recent News & Updates
Recent updates
Nxera Pharma Co., Ltd. (TSE:4565) Stocks Pounded By 25% But Not Lagging Industry On Growth Or Pricing
Sep 25
Nxera Pharma Co., Ltd.'s (TSE:4565) P/S Still Appears To Be Reasonable
Jun 26Is Nxera Pharma (TSE:4565) A Risky Investment?
Apr 06Sosei Group Corporation (TSE:4565) Stocks Shoot Up 25% But Its P/S Still Looks Reasonable
Mar 08Shareholder Returns
| 4565 | JP Pharmaceuticals | JP Market | |
|---|---|---|---|
| 7D | -0.5% | -0.9% | -0.6% |
| 1Y | -30.6% | 8.1% | 14.5% |
Return vs Industry: 4565 underperformed the JP Pharmaceuticals industry which returned 8.1% over the past year.
Return vs Market: 4565 underperformed the JP Market which returned 14.5% over the past year.
Price Volatility
| 4565 volatility | |
|---|---|
| 4565 Average Weekly Movement | 4.4% |
| Pharmaceuticals Industry Average Movement | 3.7% |
| Market Average Movement | 3.5% |
| 10% most volatile stocks in JP Market | 7.2% |
| 10% least volatile stocks in JP Market | 1.8% |
Stable Share Price: 4565 has not had significant price volatility in the past 3 months compared to the JP market.
Volatility Over Time: 4565's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 372 | Chris Cargill | www.nxera.life |
Nxera Pharma Co., Ltd. develops and sells biopharmaceutical products in Japan, Switzerland, the United States, Bermuda, and the United Kingdom. Its product portfolio products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair and Breezhaler for the treatment of asthma; ORAVI, a novel formulation for the treatment of oropharyngeal candidiasis; and PIVLAZ for the treatment of cerebral vasospasm indications. The company’s development products pipeline consists of HTL0039732 for immuno-oncology indications; HTL0048149 for schizophrenia disorders; Daridorexant for the treatment of insomnia; HTL0016878 for schizophrenia and other neuropsychiatric disorders; PF-07081532 for Type 2 diabetes mellitus and obesity; PF-07054894 for inflammatory bowel disease; PF-07258669 for anorexia; PF-06954522 for metabolic diseases; NBI-1117569 for neurology diseases; and NBI-1117570 for central nervous system (CNS) disorders.
Nxera Pharma Co., Ltd. Fundamentals Summary
| 4565 fundamental statistics | |
|---|---|
| Market cap | JP¥94.22b |
| Earnings (TTM) | -JP¥3.71b |
| Revenue (TTM) | JP¥29.28b |
3.2x
P/S Ratio-25.4x
P/E RatioIs 4565 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4565 income statement (TTM) | |
|---|---|
| Revenue | JP¥29.28b |
| Cost of Revenue | JP¥5.43b |
| Gross Profit | JP¥23.85b |
| Other Expenses | JP¥27.56b |
| Earnings | -JP¥3.71b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 14, 2025
| Earnings per share (EPS) | -41.28 |
| Gross Margin | 81.46% |
| Net Profit Margin | -12.68% |
| Debt/Equity Ratio | 95.8% |
How did 4565 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/05 09:14 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Nxera Pharma Co., Ltd. is covered by 18 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Koichi Mamegano | BofA Global Research |
| Hidemaru Yamaguchi | Citigroup Inc |
| null null | Credit Suisse |